RxDoctor Payments Data

Sakina Alston, APRN

Psychiatric/Mental Health · Mooresville, NCNPI 1073107751

Payments from drug & device makers

$1,561in general payments, 2019–2025

Across 80 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$279
  • Takeda Pharmaceuticals U.S.A., Inc.$218
  • Teva Pharmaceuticals USA, Inc.$194
  • Neurocrine Biosciences, Inc.$156
  • AbbVie$120
  • Supernus Pharmaceuticals, Inc.$111
  • plus $482 from 9 others

What the payments were for

  • Food & beverage$1,561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,561 in reported general payments places this provider in the 70th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$6,538
Medicare patients
15
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl20$29,780
AuvelityDextromethorphan Hbr/Bupropion21$21,412
TrintellixVortioxetine Hydrobromide16$14,411
Duloxetine Hcl53$1,607
Aripiprazole18$1,401
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine23$986
Lamotrigine74$684
Venlafaxine Hcl ErVenlafaxine Hcl31$556
Naltrexone Hcl12$515
Olanzapine32$458
Bupropion XlBupropion Hcl37$420
Buspirone Hcl47$412
Trazodone Hcl56$353
Prazosin Hcl23$313
Quetiapine Fumarate38$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$120$29,78020 claims
Axsome Therapeutics, Inc.Auvelity$64$21,41221 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$218$14,41116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Mooresville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →